TY - JOUR
T1 - Carotid artery stenting outcomes in high-risk patients receiving best medical therapy
T2 - Results from a single high-volume interventional cardiology practice
AU - Trusinskis, Karlis
AU - Vasiljevs, Deniss
AU - Knoka, Evija
AU - Sondore, Dace
AU - Dombrovskis, Andis
AU - Kumsars, Indulis
AU - Strenge, Karlis
AU - Bumeistere, Kristine
AU - Kareer, Gurjoat S.
AU - Erglis, Andrejs
N1 - Publisher Copyright:
© 2016
PY - 2016/12/1
Y1 - 2016/12/1
N2 - Background Carotid artery stenting (CAS) is now being widely used in the treatment of carotid artery stenosis. Recent clinical studies have demonstrated low adverse event rates after CAS. This study evaluates the 30-day and 1-year results in patients treated with CAS and receiving intensive medical therapy in a high-volume percutaneous coronary intervention center. Methods A total of 184 patients underwent CAS between January 2011 and December 2013. In addition to antiplatelet therapy, patients received intensive antihypertensive treatment, high intensity statin and heart rate normalization therapy. Patients were stratified according to age and symptomatic status. Results Most of the patients (86.4%) had at least one high surgical risk criteria. The procedural success rate was 98.4%. The 30-day and 1-year incidence of stroke were 4.1% and 4.5%, respectively. At 30 days the combined rate of stroke/cardiovascular (CV) death/myocardial infarction (MI) was 5.8% and 10.9% in 1 year. The 30-day incidence of stroke/CV death in asymptomatic and symptomatic patients was 5.4% and 4.2%, respectively. Age ≥80 years increased the risk of stroke/CV death/MI at 1 year (OR 4.41; 95% CI 1.06–18.36; P = 0.04). Conclusions The study demonstrated acceptable clinical outcome results in patients with high medical comorbidities treated with CAS and intensive medical therapy. Adverse event rate in symptomatic patients did not exceed the guideline recommended range while in asymptomatic patients it was increased.
AB - Background Carotid artery stenting (CAS) is now being widely used in the treatment of carotid artery stenosis. Recent clinical studies have demonstrated low adverse event rates after CAS. This study evaluates the 30-day and 1-year results in patients treated with CAS and receiving intensive medical therapy in a high-volume percutaneous coronary intervention center. Methods A total of 184 patients underwent CAS between January 2011 and December 2013. In addition to antiplatelet therapy, patients received intensive antihypertensive treatment, high intensity statin and heart rate normalization therapy. Patients were stratified according to age and symptomatic status. Results Most of the patients (86.4%) had at least one high surgical risk criteria. The procedural success rate was 98.4%. The 30-day and 1-year incidence of stroke were 4.1% and 4.5%, respectively. At 30 days the combined rate of stroke/cardiovascular (CV) death/myocardial infarction (MI) was 5.8% and 10.9% in 1 year. The 30-day incidence of stroke/CV death in asymptomatic and symptomatic patients was 5.4% and 4.2%, respectively. Age ≥80 years increased the risk of stroke/CV death/MI at 1 year (OR 4.41; 95% CI 1.06–18.36; P = 0.04). Conclusions The study demonstrated acceptable clinical outcome results in patients with high medical comorbidities treated with CAS and intensive medical therapy. Adverse event rate in symptomatic patients did not exceed the guideline recommended range while in asymptomatic patients it was increased.
KW - Carotid artery disease
KW - Carotid artery stenosis
KW - Carotid artery stenting
KW - Stroke
UR - http://www.scopus.com/inward/record.url?scp=84999277855&partnerID=8YFLogxK
U2 - 10.1016/j.crvasa.2015.09.005
DO - 10.1016/j.crvasa.2015.09.005
M3 - Article
AN - SCOPUS:84999277855
SN - 0010-8650
VL - 58
SP - e569-e575
JO - Cor et Vasa
JF - Cor et Vasa
IS - 6
ER -